Cellebrite Shares Plunge 29% to $10.80 After 2026 Revenue Cut
Updated
Updated · Yahoo Finance · Aug 13
Cellebrite Shares Plunge 29% to $10.80 After 2026 Revenue Cut
3 articles · Updated · Yahoo Finance · Aug 13
Summary
Cellebrite sank 29.18% to $10.80 after reporting a quarterly earnings miss and lowering full-year outlook, with 36.5 million shares traded—about 13.5 times its three-month average.
Q2 sales still rose 16%, but missed analysts' expectations, while management guided to 19.5% sales growth in Q3 and 15% growth in 2026 as net income declined from a year earlier.
That combination of slower growth and weaker profitability hit a stock that has gained only about 12% since its 2020 IPO, even as the broader market advanced and peers Axon and NICE rose.
Shiven Ramji, newly named CEO after leading Cellebrite's technology and products unit, now faces pressure to steady execution, though Guardian, Pathfinder and Corellium more than doubled sales and Genesis AI began generating revenue in Q2.